These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19695416)

  • 41. The stroke care revolution.
    Lancet Neurol; 2015 Apr; 14(4):341. PubMed ID: 25752414
    [No Abstract]   [Full Text] [Related]  

  • 42. Rapid EEG changes indicate reperfusion after tissue plasminogen activator injection in acute ischaemic stroke.
    Finnigan SP; Rose SE; Chalk JB
    Clin Neurophysiol; 2006 Oct; 117(10):2338-9. PubMed ID: 16926108
    [No Abstract]   [Full Text] [Related]  

  • 43. Thrombolysis in acute ischaemic stroke: time for a rethink?
    Alper BS; Malone-Moses M; McLellan JS; Prasad K; Manheimer E
    BMJ; 2015 Mar; 350():h1075. PubMed ID: 25786912
    [No Abstract]   [Full Text] [Related]  

  • 44. Promoting Acute Thrombolysis for Ischaemic Stroke (PRACTISE).
    Dirks M; Niessen LW; Huijsman R; van Wijngaarden J; Minkman MM; Franke CL; van Oostenbrugge RJ; Koudstaal PJ; Dippel DW;
    Int J Stroke; 2007 May; 2(2):151-9. PubMed ID: 18705977
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Further randomized controlled trials of tPA within 3 hours are required-not!
    Lyden PD
    Stroke; 2001 Nov; 32(11):2709-10. PubMed ID: 11692041
    [No Abstract]   [Full Text] [Related]  

  • 46. The 4.5-hour time window for intravenous thrombolysis with intravenous tissue-type plasminogen activator is not firmly established.
    Wechsler LR
    Stroke; 2014 Mar; 45(3):914-5. PubMed ID: 24526061
    [No Abstract]   [Full Text] [Related]  

  • 47. Alteplase is safe to use within existing treatment guidelines, says independent review.
    Torjesen I
    BMJ; 2015 Jul; 351():h4062. PubMed ID: 26215777
    [No Abstract]   [Full Text] [Related]  

  • 48. Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice.
    Gladstone DJ; Black SE
    CMAJ; 2001 Aug; 165(3):311-7. PubMed ID: 11517650
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
    Maiser SJ; Georgiadis AL; Suri MF; Vazquez G; Lakshminarayan K; Qureshi AI
    Int J Stroke; 2011 Feb; 6(1):25-32. PubMed ID: 21205237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of the stroke code activation source on the outcome of acute ischemic stroke patients.
    Whitcomb DS
    Neurology; 2009 May; 72(19):1709; author reply 1710. PubMed ID: 19433750
    [No Abstract]   [Full Text] [Related]  

  • 51. Emergency physician survey: recombinant tissue plasminogen activator for stroke.
    Walsh M; Fromm G
    Ann Emerg Med; 2006 Mar; 47(3):297. PubMed ID: 16492504
    [No Abstract]   [Full Text] [Related]  

  • 52. Breaking the 3 h barrier for treatment of acute ischaemic stroke.
    Donnan GA; Davis SM
    Lancet Neurol; 2008 Nov; 7(11):981-2. PubMed ID: 18940690
    [No Abstract]   [Full Text] [Related]  

  • 53. Estimation of Iranian stroke patients eligible for intravenous thrombolysis with tPA.
    Ghandehari K; Zahed AP; Taheri M; Abbasi M; Gorjestani S; Ahmadi AM; Nahayati MA
    Int J Stroke; 2009 Aug; 4(4):236. PubMed ID: 19689746
    [No Abstract]   [Full Text] [Related]  

  • 54. Thrombolytic therapy with alteplase for ischaemic stroke.
    Drug Ther Bull; 2009 Feb; 47(2):14-8. PubMed ID: 19193701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Use of fibrinolytic agents during surgical treatment for submacular hemorrhages of various etiology].
    Sosnovskiĭ VV; Sdobnikova SV
    Vestn Oftalmol; 2008; 124(6):47-51. PubMed ID: 19205404
    [No Abstract]   [Full Text] [Related]  

  • 56. Should more patients with acute ischaemic stroke receive thrombolytic treatment?
    Wardlaw JM; Sandercock PA; Murray V
    BMJ; 2009 Nov; 339():b4584. PubMed ID: 19906748
    [No Abstract]   [Full Text] [Related]  

  • 57. 4.5-hour time window for intravenous thrombolysis with recombinant tissue-type plasminogen activator is established firmly.
    Schellinger PD; Köhrmann M
    Stroke; 2014 Mar; 45(3):912-3. PubMed ID: 24526060
    [No Abstract]   [Full Text] [Related]  

  • 58. Hope on the horizon for stroke patients.
    Cornell DH
    N J Med; 1998 Apr; 95(4):61-3. PubMed ID: 16010797
    [No Abstract]   [Full Text] [Related]  

  • 59. Alteplase for stroke. American Heart Association explains how guidelines were formulated.
    Faxon D
    BMJ; 2002 Jun; 324(7353):1581; author reply 1581. PubMed ID: 12092606
    [No Abstract]   [Full Text] [Related]  

  • 60. Can the therapeutic window for tissue plasminogen activator be extended to 6 hours after stroke onset?
    Alexandrov AV
    Nat Clin Pract Cardiovasc Med; 2005 Jul; 2(7):342-3. PubMed ID: 16265558
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.